The SANO trial also demonstrated clinically complete responses following neoadjuvant chemoradiotherapy. Positive data from the SANO trial presented on th
Compared to chemotherapy, the SAPPHIRE study did not satisfy its primary endpoint. According to findings from the phase III th
The phase III MANTRA trial reported disappointing results, but biomarker-based approaches still offer promise for MDM2 inhibition in solid tumors.
Sunday, October 22nd 2023, Madrid,Spain : Positive results in advanced or metastatic disease from EV-302/KEYNOTE-A39 and CheckMate 901 indicate for
Friday, October 20th,2023, Madrid ,Spain: Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this
In two trials, progression-free survival was longer with tumor-specific chemotherapy than with standard chemotherapy, but more research is required to
Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this setting, which is comparable to
The JCOG1611-GENERATE trial results stimulate the debate over the optimal treatment option in this setting. A planned interim analysis on
Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this setting, which is comparable to
This paper was presented on October 20 at the ESMO Congress 2023 at Madrid. Molecular alterations (MA) may influence therapeutic